96954 ⎘
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans; Cytokines; Lymphokines; Interferons Thrombopoietin, i.e. C-MPL ligand
Genetically Modified Mice and Engraftment
#2FLT3 LIGAND BI-FUNCTIONAL MOLECULES FOR THROMBOPENIA AND ACUTE RADIATION SYNDROME
#3METHOD FOR THE MANUFACTURE OF BIOPHARMACEUTICALS
#4TPO MIMETIC FUSION PROTEINS AND METHODS OF USE
#5METHODS FOR THE PURIFICATION OF REFOLDED FC-PEPTIDE FUSION PROTEIN
#6GENETICALLY MODIFIED NON-HUMAN ANIMALS EXPRESSING HUMAN EPO
#7Genetically Modified Mice and Engraftment
#8Process for lyophilized pharmaceutical formulations of a therapeutic protein
#9Genetically modified non-human animals and methods of use thereof
#10Genetically modified non-human animals expressing human EPO
#11Genetically modified mice and engraftment
#12Use of compounds with thrombopoietic activity to promote bone growth and healing
#13PROCESS FOR LYOPHILIZED PHARMACEUTICAL FORMULATION OF A THERAPEUTIC PROTEIN
#14Messenger UNA molecules and uses thereof
#15Genetically modified non-human animals and methods of use thereof
#16Genetically modified mice and engraftment
#17Lyophilized pharmaceutical composition of Fc-peptide fusion protein
#18Use of compounds with thrombopoietic activity to promote bone growth and healing
#19Recombinant protein
#20Genetically modified non-human animals expressing human EPO
#21Thrombopoietic compounds
#22Rationally designed antibodies
#23Genetically modified mice and engraftment
#24METHOD OF IMPROVING EFFICACY OF BIOLOGICAL RESPONSE-MODIFYING PROTEINS AND THE EXEMPLARY MUTEINS
#25Agonist antibody to human thrombopoietin receptor
#26Genetically modified mice and engraftment
#27Genetically modified mice and engraftment
#28Chemokine-Mucin Fusions Linked to Glycosylphosphatidylinositol (GPI)-Anchors in Tissue Regeneration and as Tumour Immune Adjuvants
#29Thrombopoietic compounds
#30Method for preparing recombinant glycoproteins with high sialic acid content
#31Spacer moiety for poly(ethylene glycol) modified peptide based compounds
#32Agonist antibody to human thrombopoietin receptor
#33Thrombopoietic compounds
#34Thrombopoietic compounds
#35Cytokines and Cytokine Receptors with Reduced Immunogenicity
#36Peptides and Related Compounds Having Thrombopoietic Activity
#37Genetically modified mice and engraftment
#38Thrombopoietic Compounds
#39IMMUNOGLOBULIN FUSION PROTEINS
#40METHOD OF IMPROVING EFFICACY OF BIOLOGICAL RESPONSE-MODIFYING PROTEINS AND THE EXEMPLARY MUTEINS
#41Rationally designed antibodies
#42CHIMERIC NON-HUMAN ANIMAL
#43Agonist antibody to human thrombopoietin receptor
#44Cytokines and Cytokine Receptors With Reduced Immunocencity
#45PEPTIDES AND COMPOUNDS THAT BIND TO A RECEPTOR
#46Thrombopoietic compounds
#47Rationally designed antibodies
#48Compositions and methods for producing bioactive fusion proteins
#49Thrombopoietic compounds
#50Peptides and related compounds having thrombopoietic activity
#51TPO peptide compounds for treatment of anemia
#52Thrombopoietic compounds
#53Process for Purifying Human Thrombopoietin with High Content of Sialic Acid
#54Peptides and compounds that bind to a receptor
#55Thrombopoietic compounds
#56Multi-functional chimeric hematopoietic receptor agonists
#57Modified peptides as therapeutic agents
#58Spacer moiety for poly (ethylene glycol) modified peptide based compounds
#59Thrombopoietic compounds
#60Thrombopoietin proteins with improved properties
#61Peptides and compounds that bind to a receptor
#62Thrombopoietin protein variants
#63Cytokines and cytokine receptors with reduced immunogenicity
#64Amyloid-β protein aggregation-regulating factors
#65Human thrombopoietin comprising glycosylation sited at residues 157 and 164
#66Chimeric nonhuman animal
#67Peptides and compounds that bind to a receptor
#68Modified peptides as therapeutic agents
#69Thrombopoietic compounds